Expression and clinical significance of cancer-related gene MPS-1 in gastric cancer.
- Author:
Yun-wei WANG
1
;
Zheng-gang ZHU
;
Bing-ya LIU
;
Qin-long GU
;
Jian-fang LI
;
Ying QU
;
Xue-hua CHEN
;
Yan-zhen LIN
Author Information
- Publication Type:Journal Article
- MeSH: Cell Cycle Proteins; genetics; Cell Line, Tumor; Female; Humans; Male; Oligonucleotide Array Sequence Analysis; Protein-Serine-Threonine Kinases; genetics; Protein-Tyrosine Kinases; RNA, Neoplasm; genetics; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; genetics; metabolism; pathology
- From: Chinese Journal of Gastrointestinal Surgery 2005;8(6):503-506
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of cancer-related gene MPS-1 in gastric cancer and to evaluate its significance in clinical diagnosis and therapy.
METHODSThe mRNA expression of MPS-1 was determined by polymerase chain reaction after reverse transcription (RT-PCR) in cancer tissues and adjacent non-cancerous tissues from 42 cases with gastric cancer. The expression levels of MPS-1 in 6 gastric cancer cell lines (AGS, MKN-45, SGC 7901, KATO III, N-87 and SNU-1) were also determined by RT-PCR and Western blot.
RESULTSThe MPS-1 mRNA was expressed in all tissues and cell lines. The mRNA expression level of MPS-1 in cancer tissues were 1.37+/- 0.87, significantly higher than 0.99+/- 0.67 in adjacent normal gastric mucous tissues (P< 0.01). The expression of MPS-1 was correlated with TNM stage (P< 0.05), but not with age, gender, tumor size and differentiation. The expression level of MPS-1 mRNA in the primary lesions was hig her in the patients with TNM stages III, IV than those with TNM stages I, II. Meanwhile, RT-PCR and Western blot showed the same results that MPS-1 expression was higher in the six gastric cancer cell lines as compared with that in the normal gastric cell line GES-1.
CONCLUSIONThe high expression of MPS-1 in gastric cancer indicates that MPS-1 might play an important role in gastric carcinogenesis,which may provide a new target in immunotherapy for gastric cancer.